ArticleScientific reports2025
Pharmacovigilance analysis of spondyloarthritis following HPV vaccination based on the VAERS database.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Analysis of vaccine adverse events associated with rheumatoid arthritis: A pharmacovigilance study based on the VAERS database.Human vaccines & immunotherapeutics · 2026Article
- Pharmacovigilance signal detection of central nervous system demyelinating diseases following human papillomavirus vaccination: data mining and signal analysis based on the VAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
HPV vaccine is an important biological product that contributes to disease prevention and control and public health system construction, and it shows an increasing vaccination rate year by year. Based on this high vaccination rate, it has brought about many adverse events. The aim of this study was to investigate the association between real world HPV vaccine and spondyloarthritis. Data from Vaccine Adverse Event Reporting System (VAERS) through January 1, 2025 were included in the study. Four pharmacovigilance analysis methods and bonferroni corrected P-values were utilized to uncover associations between HPV vaccines and spondyloarthritis. In addition, subgroup analyses were utilized to explore populations with different characteristics. Complementarily, time to induction analysis and Weibull distribution analysis were utilized to expand the research horizons. Of the 60,840 HPV vaccine-related adverse events recorded in the VAERS database during the study period, 141 could be attributed to spondyloarthritis. Of these, juvenile idiopathic arthritis and reactive arthritis were monitored for warning signs of positive significance. The results of the subgroup analysis showed that the gender was female and the age group was lower was found to have higher positive signals for adverse events. Weibull distribution analysis showed that the vaccine had an early-onset profile, HPV vaccine-induced spondyloarthritis was progressive and decreasing over time. This study suggests an association between HPV vaccine and spondyloarthritis with different predisposing risks in different patient populations and treatment stages. Patients should be closely monitored for spondyloarthritis-related markers and assessed for risk during HPV vaccination. This study provides more comprehensive insights into HPV vaccine safety and the understanding of spondyloarthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.